Merck Prices $4.5 Billion Debt Offering
June 17 2020 - 6:30AM
Business Wire
Merck (NYSE: MRK), known as MSD outside the United States and
Canada, yesterday priced a $4.5 billion public offering of four
series of senior unsecured notes (collectively, the “Notes”). The
Notes include:
$1.0 billion of 0.750% notes due 2026 $1.25
billion of 1.450% notes due 2030 $1.0 billion of 2.350% notes due
2040 $1.25 billion of 2.450% notes due 2050
Merck intends to use the net proceeds from the offering for
general corporate purposes, including without limitation the
repayment of outstanding commercial paper borrowings and other
indebtedness with upcoming maturities. The offering is expected to
close on June 24, 2020, subject to customary closing conditions.
BNP Paribas Securities Corp., BofA Securities, Inc., Citigroup
Global Markets Inc. and Deutsche Bank Securities Inc. are acting as
the active joint book-running managers for the offering.
The offering of the Notes is being made pursuant to an effective
shelf registration statement (including a base prospectus) filed
with the Securities and Exchange Commission (the “SEC”). The
offering may be made only by means of a prospectus and related
prospectus supplement, copies of which may be obtained by calling
BNP Paribas Securities Corp. toll-free at 1-800-854-5674, BofA
Securities, Inc. collect at 1-800-294-1322, Citigroup Global
Markets Inc. toll-free at 1-800-831-9146 or Deutsche Bank
Securities Inc. toll-free at 1-800-503-4611. An electronic copy of
the registration statement and prospectus supplement, together with
the base prospectus, is available on the SEC’s website at
www.sec.gov.
This press release does not constitute an offer to sell or a
solicitation of an offer to buy the securities described herein,
nor shall there be any sale of these securities in any state or
jurisdiction in which such an offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such jurisdiction.
About Merck
For more than 125 years, Merck, known as MSD outside of the
United States and Canada, has been inventing for life, bringing
forward medicines and vaccines for many of the world’s most
challenging diseases in pursuit of our mission to save and improve
lives. We demonstrate our commitment to patients and population
health by increasing access to health care through far-reaching
policies, programs and partnerships. Today, Merck continues to be
at the forefront of research to prevent and treat diseases that
threaten people and animals – including cancer, infectious diseases
such as HIV and Ebola, and emerging animal diseases – as we aspire
to be the premier research-intensive biopharmaceutical company in
the world.
Forward-Looking Statement of Merck & Co., Inc.,
Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J.,
USA (the “company”) includes “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. Such statements may
include, but are not limited to, the company’s ability to complete
the offering and the company’s expectations for the use of proceeds
from the offering. These statements are based upon the current
beliefs and expectations of the company’s management and are
subject to significant risks and uncertainties. If underlying
assumptions prove inaccurate or risks or uncertainties materialize,
actual results may differ materially from those set forth in the
forward-looking statements.
Risks and uncertainties include but are not limited to, general
industry conditions and competition; general economic factors,
including interest rate and currency exchange rate fluctuations;
the impact of the recent global outbreak of novel coronavirus
disease (COVID-19); the impact of pharmaceutical industry
regulation and health care legislation in the United States and
internationally; global trends toward health care cost containment;
technological advances, new products and patents attained by
competitors; challenges inherent in new product development,
including obtaining regulatory approval; the company’s ability to
accurately predict future market conditions; manufacturing
difficulties or delays; financial instability of international
economies and sovereign risk; dependence on the effectiveness of
the company’s patents and other protections for innovative
products; and the exposure to litigation, including patent
litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be found in the company’s 2019
Annual Report on Form 10-K and the company’s other filings with the
Securities and Exchange Commission (SEC) available at the SEC’s
Internet site (www.sec.gov).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200617005160/en/
Media: Pamela Eisele (267) 305-3558 Jennifer Mauer (908)
740-1801 Investors Peter Dannenbau (908) 740-1037 Michael DeCarbo
(908) 740-1807
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2023 to Apr 2024